Cost-effectiveness of PEP programs can be optimized by attempting to target prophylaxis to only individuals with high-risk exposures[Pinkerton 2004a]
Private insurance may pay for prophylactic antiretroviral agents, but state Medicaid programs often decline to provide antiretroviral agents for persons who are HIV uninfected[Landovitz 2009]
Local organizations have assumed challenge of developing nontraditional methods for funding PEP for uninsured and Medicaid patients[Landovitz 2009]
Action required
Login now to access all of your entitled content
or
